In the course of antifungal screening, pradimicins A, B and C were found in the culture of Actinomadura hibisca No. P157-2 (ATCC ttSl)1"^and their chemical structures were determined to be a benzo [a] naphthacenequinone substituted by a D-alanine and sugars4" 7). This paper describes their in vitro and in vivo antifungal activities. Pradimicin A has been extensively evaluated for in vivo therapeutic activity in a variety ofmurine systemic and local fungal infections, for acute toxicity in mice and for other biological activities.
Materials and Methods
Antifungal Agents Pradimicins A, B and C were prepared at Bristol-Myers Research Institute Co., Tokyo and used after dissolving in saline containing 10% DMSOand adjusting to pH7.5 with 1.0n NaOH. Amphotericin B (Fungizone, sodium deoxycholate complex) was purchased from Squibb, Japan and used by dissolving in saline for both in vitro and in vivo experiments. Ketoconazole was obtained from Janssen Pharmaceuticals and used as a suspension in saline containing 10%DMSO. 5-Fluorocytosine purchased from Sigma Chemical Companywas dissolved in saline.
In Vitro Antifungal Activity The MICsof the antifungal agents were determined by an agar dilution method on yeast morphology agar adjusted to pH7.0 with 1/15m phosphate buffer. A 5-jul aliquot of fungal suspension containing 106 cells/ml, except for Trichophyton mentagrophytes No. 4329 which contained 107 cells/ml, was inoculated onto the surface of the antibiotic-containing agar plates with a multiinoculator. After incubation at 28°C for 40 hours, the lowest concentration of antibiotic causing virtually complete inhibition of fungal growth 1 Deceased.
(MIC) was determined.
In Vivo Antifungal Activity THE JOURNAL OF ANTIBIOTICS JULY 1990 Systemic Fungal Infections in Normal Mice: The in vivo therapeutic efficacy of pradimicins A, B and C was examined comparatively with amphotericin B and ketoconazole against systemic infection with C. albicans A9540 (106 cells/mouse), 5-fluorocytosine-resistant C. albicans YA22851 (5.5 x 105 cells/mouse), azole-resistant C. albicans YA26090(8.8 x 105cells/mouse), Cryptococcus neoformans IAM4514 (106 cells/mouse) or Aspergillusfumigatus IAM2034 (107 cells/mouse) in normal mice. C. albicans and C. neoformans were cultured at 28°C for 18 and 48 hours, respectively, in YGPmedium (glucose 1.5%, peptone 1.0%, yeast extract 0.4%, K2HPO40.05% and MgSO4-7H2O0.05%, pH7.0) and suspended in saline. A. fumigatus was cultured at 28°C for 7 days on YGPagar slant and the spores were suspended in saline. Male ICR mice weighing 20 to 24g were infected iv with approximately 10 times the median lethal doses of each fungus as shownabove. Groups of 5 mice at each dose level were given the test compounds by iv or im dosing route. The initial treatment was given immediately after the fungal challenge. The 50% protection dose (PD50) was calculated by the method of Litchfield and Wilcoxon8) from the survival rate recorded 20 days after the fungal challenge. Untreated animals died 7 to 15 days post infection.
Systemic Fungal Infections in Immunocompromized Mice: Groups of 5 male ICR mice weighing 20 to 24g were treated ip with 200mg/kg of cyclophosphamide 4 days before C. albicans A9540, Candida tropicalis CS-07, C. neoformans IAM4514 or A.fumigatus IAM2034 iv infection at 2.2 x 105, 2.3 x 106, 2.9 x l05 or 2.0 x l06 cells/mouse (10 times LD50), respectively. Test compounds were administered iv or im to the mice. The initial treatment was done immediately after the fungal challenge.
Lung C. albicans and A. fumigatus Infections: Groups of 4 male ICR mice weighing 20 to 25 g were treated ip with 200mg/kg of cyclophosphamide 4 days before the lung infection with C. albicans A9540 or A. fumigatus IAM2034. The mice were anesthetized with ether and were infected with a 70-^ul of C. albicans or A. fumigatus cell suspension containing 1 x 106 or 1.1 x 108 cells, respectively, through an intranasal route on day 0. Test compounds were administered iv to the mice immediately after the inoculation followed by once a day administration on days 2 and 4. The PD50was calculated from the survival rate recorded 20 days after the fungal challenge.
Vaginal C. albicans Infection: Groups of 5 female ICR mice weighing 20 to 24 g were treated sc with 0.5 mg/kg of estradiol benzoate 3 days before and 2 days after vaginal infection with C. albicans A9540. A 10-ju1 portion of a cell suspension of C. albicans containing 106 cells was inoculated intravaginally on day 0. Test compounds were administered im to the mice immediately after the inoculation followed by once a day for 4 days. On day 7, vaginal exudate was sampled with a thin glass rod and spread on an YGPagar plate containing 100/jg/ml of chloramphenicol. The plate was incubated at 28°C for 2 days. Viable cell count was made and graded by the scores indicated in Table 1 .
Skin T. mentagrophytes Infection: Groups of 5 male ICR mice weighing 20 to 25 g were anesthetized ip with 35 mg/kg of pentobarbital. After removing the hair from the back (approx 2cm2), the skin was gently injured with sandpaper and vaccination needles. A 100-jul sample of cell suspension of T.
mentagrophytes No. 4329 containing 5 x 105 cells was applied to the injured skin on day 0. Test compounds were mixed with Solbase (50% macrogol 400, Dainippon Pharmaceutical Co.) and topically spread around the infected area with a glass rod (once a day on days 0 to 4). On the day 7, lesions of the infected area were graded according to the severity of the infection by the scores indicated in Table 2 . Madin Darby canine kidney (MDCK), green monkey kidney (Vero) and murine melanoma (B16-F10) cells were grown to the logarithmic phase in Eagle minimumessential medium (MEM)supplemented with fetal calf serum (FCS, 10% in MDCKand B16-F10 cells, and 5% in Vero cells) and antibiotic (50/zl/ml of amikacin in MDCK and Vero cells, and 60/ig/ml of kanamycin in B16-F10 cells). Humancolon carcinoma (HCT-116) cells were grown in McCoy's 5A medium supplemented with FCS (10%), benzylpenicillin (lOOu/ml) and streptomycin (100^g/ml) at 37°C in a humidified atmosphere of 5% CO2 and 95% air. MDCKcells were obtained from the American Type Culture Collection (Rockville, MD) and the other cell lines were from Bristol-Myers Squibb Company (Wallingford, CT). MDCK, Vero, B16-F10 and HCT-116cells were harvested and a 180-/J aliquot of cell suspension was implanted into wells ofa 96-well microplate at the inoculum sizes of 1 x 105, 1 x 105, 3 x 104 and 6 x 104 cells/ml, respectively, and incubated for 24 hours. After adding test compounds (20^1), they were further incubated for 72 hours. The cytotoxicity was colorimetrically determined at 540 nm after staining viable cells with 0.006% neutral red solution.
Acute Toxicity in Mice
Pradimicin A was dissolved in saline containing 10% DMSO. The test compoundsolution was adjusted to pH7.5 with 1.0n NaOHand injected iv or im once to groups of 5 male ICR mice at a dose volume of 0.2ml per 10g body weight. The animals were observed daily for 10 days for physical and behavioral signs of toxicity.
In Vitro Antiviral Activity Determined by the Plaque Reduction Assay MDCK and Vero cells were grown in Eagle MEMsupplemented with FCS (10% for MDCK cells, 5% for Vero cells) and 50/ig/ml of amikacin. Influenza virus type A Victoria and herpes simplex virus type 1 (HSV-1) KOSstrains were grown on MDCKand Vero cells, respectively. In the anti-influenza virus assay, con fluent MDCK cell monolayers were grown in a 12-well microplate and the mediumdrained from the culture and washed with Eagle MEM. The culture was infected with 20~30 pfu/well of the virus in Eagle MEMcontaining trypsin. After adsorption for 1 hour at 37°C, unadsorbed viruses were removed and 2 ml of an overlay of Eagle medium with 0.25% agarose containing 2-fold dilutions of test compound were added. The culture was incubated at 37°C in a humidified atmosphere of 5% CO2and 95% air for 48~72 hours until the plaques were observed. After removing the overlay medium, cell monolayers were fixed with 10%formaldehyde solution and the plaques were counted. In the anti-HSV assay, Vero cell monolayers were grown in a 24-well microplate and the mediumwas drained from the culture, which was washed with Eagle MEM.The cultures were inoculated with approximately 50 pfu/well of HSV-1. After adsorption for 1 hour at 37°C, unadsorbed viruses were removed and the cultures were overlayed with 1 ml of Eagle MEMcontaining 0.3% immune serum globulin and 2-fold dilutions of the test compound. The cultures were incubated at 37°C for 48~72 hours until the plaques were observed. After removing overlay medium, cell monolayers were stained with carbol-fuchsin and the plaques were counted.
Results
In Vitro Antifungal Activity MICs for pradimicins A, B and C, amphotericin B and ketoconazole against 16 different fungi and yeasts are shown in Table 3 . Pradimicin A showed weaker activity than amphotericin B but inhibited a wide range of fungi and yeasts tested with MICvalues of 0.8~12.5 jug/ml except for Mucor spinosus which showed no susceptibility at 100 //g/ml. Both pradimicins B and C exhibited similarly broad antifungal spectra while no or weak inhibition was seen against Fusarium moniliforme, Petriellidium boydii or M.
spinosus. All pradimicins possessed significantly stronger anti-Candida activity than ketoconazole. In Vivo Antifungal Activity against Systemic Infections in Mice In vivo anti-Candida activity of pradimicins A, B and C was examined in the systemic C. albicans Table 3 . Antifungal spectrum of pradimicins A, B and C by an agar dilution methoda JULY 1990 MIC Gug/ml) b 5-Fluorocytosine-resistant C. albicans. c Azole-resistant C. albicans. Inoculum size: 10LDsn-A9540 infection in mice by iv (single*) or im (bid x 2f) administration.
The results are summarized in Table 4 . Pradimicins A, B and C were active against systemic candidiasis with PD50 values of 7.9~14 mg/kg iv and 16~22mg/kg/dose im. They were 3~6 times more potent than ketoconazole but 30~80 times less potent than amphotericin B. Against 5-fluorocytosine-and azole-resistant C. albicans infections, both pradimicin A and amphotericin B were effective at the same dose level by a single iv administration as they were against sensitive C. albicans A9540infection (Table 5 ). Ketoconazole and 5-fluorocytosine were inactive against both resistant Candida strains at 50 and 100 mg/kg iv, respectively. By single iv and bidx2 im administrations, pradimicin A also showed significant protective effects on systemic infections with C. neoformans IAM 4514 and A.fumigatus IAM 2034 in mice with PD50 values of 8.9 and 21mg/kg iv, and 4.5 and 22 mg/kg/dose im, respectively (Table 6 ). Pradimicin A exhibited good therapeutic efficacy in immunocompromized mice infected systemically with C. albicans A9540, C. tropicalis CS-07, C. neoformans (Table 7) . Anti-C. albicans activity of pradimicin A was also seen with bid x 2 im treatment.
In Vivo Antifungal Activity against Lung Infections in Mice Pradimicin A and amphotericin B were tested for therapeutic effects on murine lung infections with C. albicans A9540 and A.fumigatus IAM2034 by an intravenous q2d x 3 dosing schedule. As summarized in Table 8 , both pradimicin A and amphotericin B significantly protected against lethality of mice with lung candidiasis and aspergillosis, the PD50 values of pradimicin A being 18 and 23mg/kg/dose, respectively.
In Vivo Antifungal Activity against Vaginal and Skin Infections in Mice The therapeutic efficacy of pradimicin A and amphotericin B was compared against vaginal infec- In both iv and topical treatments, test compounds were administered by qd x 5 schedule and their ED50or EC50values were calculated on day 7 after the fungal challenge. tion with C. albicans A9540 by qdx 5 iv and topical treatments in mice. As shown in Table 9 In vitro cytotoxicity of pradimicin A was determined against various cultured mammaliancells. As shown in Table 10 , pradimicin A was not cytotoxic against all cells tested at 100 or 500/xg/ml. The LD50 values in mice were 120 and more than 400mg/kg by iv and im administrations, respectively. Transient body weight loss was observed in the mice injected at higher doses than 20 and 50mg/kg by iv and im administrations, respectively. Antiviral Activity In vitro antiviral activity of pradimicin A was determined against influenza and herpes simplex viruses by the plaque reduction assay. As shown in Table 1 1 , pradimicin A potently inhibited replication of influenza virus with an IC50 value of 6.8 /jg/ml without cytotoxic activity against host MDCKcells at 200^g/ml.
Discussion
Pradimicins A, B and C are novel antifungal antibiotics produced by A. hibisca No. P157-2 (ATCC 53557)1~7). They showed potent in vitro antifungal activity and broad antifungal spectrum against a wide variety of fungi and yeasts. Antibacterial activity of pradimicin Awas seen against only Micrococcus luteus with a MICvalue of 3. 1 fig/ml1~3 ). The in vitro results suggested their broad therapeutic efficacy in systemic fungal infections, though their in vitro potencies were significantly less than that of amphotericin B. In fact, pradimicins A, B and C all exhibited significant protection in the systemic infection with C. albicans A9540, which is sensitive to various types of antifungal agents, at similar dose levels by either single iv (PD5O =7.9~14mg/kg) or bid x 2 im (PD50 = 16~21 mg/kg/dose) administration.
Pradimicin A was also significantly effective on the systemic infections with azole-or 5-fluorocytosine-resistant C. albicans, A. fumigatus IAM2034 and C. neoformans IAM4514 by the same treatment conditions as above. In immunocompromized mice, pradimicin A was active against systemic infections with C. tropicalis CS-07 as well as the above three pathogens. Pradimicin A was 2~4 times less active against C. albicans, C. neoformans or A.fumigatus in immunocompromized mice than in normal mice by a single iv administration in terms of PD50values, but its anti-Candida activity was equivalent in immunocompromizedand normal mice with bid x 2 im treatment. As described above, pradimicin A showed excellent in vivo antifungal activity against various systemic fungal infections in both normal and immunocompromized animals.
Since, most deep fungal infections are knownto be caused by species of Candida, Aspergillus and
Cryptococcus neoformans particularly frequently in immunocompromizedpatients having cancer, AIDS etc., the above results strongly suggest the clinical usefulness of pradimicin A against a variety of systemic fungal infections.
In the experimental lung infection with C. albicans or A. fumigatus, and the vaginal infection with C albicans, pradimicin A showed significant therapeutic efficacy by iv administration.
Furthermore, the antibiotic inhibited both vaginal and skin infections with C. albicans and T. mentagrophytes, respectively, with topical application. In vaginal candidiasis, the EC50 value of pradimicin A was 0.33%, which is a clinically applicable concentration. Pradimicin A was not cytotoxic to various cultured mammaliancells at 10 to 100 times higher concentrations (100~500 jUg/ml) than the antifungal MIC values (0.8~12.5 /ig/ml). In the acute toxicity experiments in mice, the LD50 values were 120 and more than 400mg/kg by iv and im administrations, respectively. Pradimicin A was found to possess a Ca+ +-dependent binding capability to yeast cell surfaces but not to mammaliancell membranes9). These results suggest that the specific binding to fungal cell surfaces plays, in part, a role in the selective toxicity of pradimicin A against fungal cells. The antibiotic had no mutagenic potential in the Amestest and the E. coli reverse mutation assay (unpublished data).
In addition to the antifungal activity, pradimicin A inhibited influenza virus replication in MDCK cells with an IC50 value of 6.8/zg/ml without cytotoxicity at 200//g/ml. Recently Yamamotoet al.10) reported that pradimicin A suppressed the cell damage induced by HIVat concentrations more than 3.5jUg/ml and suggested its anti-HIV effects on the stage of viral adsorption and cell to cell infection. Taking into consideration the serious systemic fungal infections in AIDSpatients, it would be worthwhile to study pradimicin A in the treatment of AIDSpatients.
